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Abstract
Background: Patients with diabetes and ischemic heart disease (IHD) are at high risk for adverse
cardiac outcomes. Clinical practice guidelines recommend multiple cardioprotective medications
to reduce recurrent events. We evaluated the association between cardioprotective medication
adherence and mortality among patients with diabetes and IHD.
Methods: In a retrospective cohort study of 3,998 patients with diabetes and IHD, we evaluated
use of ACE inhibitors or angiotensin receptor blockers, β-blockers, and statin medications. Receipt
of cardioprotective medications was based on filled prescriptions. Medication adherence was
calculated as the proportion of days covered (PDC) for filled prescriptions. The primary outcome
of interest was all-cause mortality.
Results: The majority of patients (92.8%) received at least 1 cardioprotective medication. Patients
receiving any medications had lower unadjusted mortality rates compared to patients not receiving
any medications (7.9% vs. 11.5%; p = 0.03). In multivariable analysis, receipt of any cardioprotective
medication remained associated with lower all-cause mortality (OR 0.65; 95% CI 0.43–0.99).
Among patients receiving cardioprotective medications, the majority (80.3%) were adherent (PDC
≥ 0.80). Adherent patients had lower unadjusted mortality rates (6.7% vs. 12.1%; p < 0.01). In
multivariable analysis, medication adherence remained associated with lower all-cause mortality
(OR 0.52; 95% CI 0.39–0.69) compared to non-adherence. In contrast, there was no mortality
difference between patients receiving cardioprotective medications who were non-adherent
compared to patients not receiving any medications (OR 1.01; 95% CI 0.64–1.61).
Conclusion: In conclusion, medication adherence is associated with improved outcomes among
patients with diabetes and IHD. Quality improvement interventions are needed to increase
medication adherence in order for patients to maximize the benefit of cardioprotective
medications.
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Background
Diabetes is prevalent and an important risk factor for the
development of ischemic heart disease (IHD). Approxi-
mately 20% of patients with diabetes have IHD, and
patients with both conditions are at particularly high risk
of for adverse outcomes [1,2]. Practice guidelines recom-
mend at least four pharmacologic agents to reduce the risk
of adverse cardiac events in this population, including
antiplatelet agents, β-blockers, HMG-CoA reductase
inhibitors, and angiotensin-converting enzyme (ACE)
inhibitors [3,4].
Prior studies suggest, however, that adherence to chronic
cardioprotective medications is suboptimal, which may
limit the potential benefits of these therapies [5]. In one
study, only 21% of patients with IHD were consistently
taking the combination of aspirin, β-blockers, and lipid-
lowering therapy [6]. In addition, another study found
that only 36% of IHD patients were still adherent with sta-
tin medications 2 years after the index prescription [7].
Prior studies, however, have not evaluated the association
between cardioprotective medication adherence, and
mortality among patients with diabetes and IHD.
Accordingly, the objective of this study was to evaluate the
relationship between cardioprotective medication (i.e.,
angiotensin-converting enzyme inhibitors, β-blockers,
and HMG-CoA reductase inhibitors) use and outcomes
among patients with diabetes and IHD. Specifically, we
assessed the association between receipt of 1 or more car-
dioprotective medications and mortality. Second, among
patients receiving cardioprotective medications, we
assessed the association between medication adherence
and mortality. The findings of this study may have impor-
tant implications for identifying gaps in the care of
patients with diabetes and IHD, as well as the develop-
ment of interventions to improve patient outcomes.
Methods
Study setting
Kaiser Permanente of Colorado (KPCO) is an integrated,
nonprofit Managed Care Organization (MCO) that pro-
vides medical services to more than 400,000 members in
the Denver, Colorado metropolitan area. A diabetes dis-
ease registry was established on September 17, 2002.
Patients with diabetes who are 18 years of age or older are
initially identified by an algorithm applied to KPCO auto-
mated databases consisting of pharmacy records (e.g., oral
hypoglycemics, or insulin), laboratory data (e.g., hemo-
globins A1C or glucose lab results), hospitalization
records and outpatient diagnoses. Once a potential
patient is identified, the diagnosis of diabetes is validated
by chart review before inclusion in the registry.
Patients
We conducted a retrospective cohort study of patients
with ischemic heart disease enrolled in the KPCO diabetes
registry. Patients who were in the registry as of September
17, 2002 and had continuous enrollment through
December 31, 2003, were included. Receipt of cardiopro-
tective medication(s) and medication adherence was
assessed during calendar year 2003. The outcomes were
ascertained from January 1, 2004 through April 30, 2005,
which was the most recent date that follow-up data was
available.
The diagnosis of ischemic heart disease was based on ICD-
9 (International Classification of Diseases, 9th Revision),
CPT (Current Procedural Terminology) and/or DRG
(Diagnosis-Related Group System) codes. We only
included patients with a diagnosis of acute myocardial
infarction based on ICD-9 or DRG codes, and/or under-
went a coronary revascularization procedure (i.e., percuta-
neous coronary intervention or coronary artery bypass
graft surgery). These criteria have been found to be highly
specific for IHD [8]. Based on the above criteria, 3,998
patients were identified and comprise the cohort for the
study.
Baseline patient demographics, co-morbidities, vital
signs, and laboratory data were derived from the auto-
mated KPCO databases, including pharmacy records, lab-
oratory data, hospitalization records and outpatient
diagnoses. For laboratory data, the baseline LDL choles-
terol and hemoglobin A1C levels were defined as the most
current measurement during calendar year 2002. For
blood pressure data, if 2 or more measurements were
available in 2002, the two most recent measurements
were averaged. Patients were followed until death or dis-
enrollment from the health plan. As of April 30, 2005,
97.1% of the patients were still enrolled or had died.
Medications
KPCO has an automated pharmacy that records all medi-
cations dispensed at each outpatient facility. Almost all
patients, 98%, have prescription drug coverage for a nom-
inal copayment. The nominal copayment and the conven-
ience of pharmacies located at the same site as the
healthcare provider's offices serve as incentives for
patients to fill their prescriptions within the system.
Cardioprotective medications
The receipt of 1 or more cardioprotective medication(s)
was based on any filled prescriptions for angiotensin-con-
verting enzyme (ACE) inhibitors, angiotensin receptor
blockers (ARB), β-blockers, or HMG-CoA reductase inhib-
itors using the KPCO pharmacy records. Patients were cat-
egorized as having a cardioprotective medication if a
prescription was filled for at least one of the indicatedBMC Cardiovascular Disorders 2006, 6:48 http://www.biomedcentral.com/1471-2261/6/48
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medications during calendar year 2003. In our primary
analysis, we considered ARBs as an ACE-inhibitor equiva-
lent medication. Therefore, patients were also categorized
as having a cardioprotective medication if a prescription
was filled for an ARB in calendar year 2003. Only 38
patients (<1%) in the entire cohort filled a prescription for
an ARB and none of the other cardioprotective medica-
tions.
Medication adherence
Medication adherence was calculated as the proportion of
days covered (PDC), based on the total number of days
supplied for filled prescriptions over the observation time
interval [9]. We defined this time interval as a minimum
of 90 days and maximum of 365 days to ensure stable esti-
mates for refill adherence in our primary analysis. A PDC
was derived for each of the classes of medications impor-
tant to patients with diabetes and IHD, and recom-
mended by national guidelines, including angiotensin-
converting enzyme inhibitors or ARBs, β-blockers, and
HMG-CoA reductase inhibitors (statins) [3,4]. For
patients prescribed multiple classes of medications, a
summary PDC was calculated based on the averaged PDC
for all of the medications. In the primary analysis, patients
were classified as 'adherent' based on a summary PDC ≥
0.80, consistent with the dichotomization of medication
adherence in the literature [10-16]. Applying this algo-
rithm, a summary PDC was calculated for 3,696 patients
with diabetes and IHD.
Dependent or outcome variable
The primary outcome of interest was all-cause mortality
during the follow-up period. Data on mortality was
derived from the KPCO automated databases and vali-
dated by comparison with other internal KPCO data
sources.
Statistical analysis
Baseline demographic factors, co-morbidities, and the
proportion of patients attaining A1C, BP and LDL guide-
line indicated levels were compared between patients
receiving 1 or more versus none of the cardioprotective
medications using the chi-square test for categorical vari-
ables and t-test for continuous variables. Next, the rela-
tionship between receipt of cardioprotective medications
and all-cause mortality was evaluated using the chi-square
test.
In multivariable analysis, logistic regression models were
constructed to evaluate the independent association
between receipt of 1 or more cardioprotective medica-
tion(s) and mortality. Models were built by applying
backward regression (p < 0.10 to enter and p < 0.05 to
remain in the model) to the variables listed in Table 1 and
included patient demographic factors, co-morbidities,
and baseline A1C, BP and LDL levels. Then, the receipt of
any cardioprotective medication variable was entered into
this baseline risk model to determine its association with
mortality. Odds ratios and 95% confidence intervals were
calculated for each independent variable in the multivari-
able models.
Next, to evaluate the association between medication
adherence and mortality, the cohort was restricted to
patients receiving 1 or more cardioprotective medications
(n = 3,696). Baseline characteristics were compared
between adherent and non-adherent patients using the
same statistical methods previously described. All-cause
Table 1: Baseline characteristics of patients with diabetes and ischemic heart disease (n = 3,998).
Variable No cardioprotective medication 
(n = 288)
1 or more cardioprotective medication(s) 
(n = 3710)
p-value
Male 50.7 61.6 <0.01
Age, mean (STD) 67.3(14.5) 69.3(9.8) 0.02
Hypertension 74.3 92.5 <0.01
Prior myocardial infarction 46.5 46.6 0.97
Peripheral vascular disease 8.0 10.2 0.24
Cerebrovascular disease 30.9 34.1 0.27
Chronic obstructive pulmonary disease 29.9 28.6 0.66
Heart failure 25.3 36.3 <0.01
Sleep apnea 20.1 23.4 0.21
Renal insufficiency 10.4 15.4 0.02
Retinopathy 6.9 6.6 0.82
Hypercholesterolemia 45.1 85.3 <0.01
Blood pressure <130/80 mm Hg at baseline 47.9 39.5 <0.01
LDL cholesterol <100 mg/dl at baseline 78.8 73.6 0.05
Hemoglobin A1C <7% at baseline 64.2 45.7 <0.01BMC Cardiovascular Disorders 2006, 6:48 http://www.biomedcentral.com/1471-2261/6/48
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mortality was compared between the two patient adher-
ence groups using the chi-square test. In multivariable
analysis, logistic regression models were constructed in a
similar fashion as the risk models for cardioprotective
medications to evaluate the independent association
between medication adherence and mortality.
In secondary analysis, we performed survival analyses and
constructed multivariable Cox proportional hazards mod-
els to assess the relationship between receipt of 1 or more
cardioprotective medication(s) and medication adher-
ence with time to death due to any cause during the fol-
low-up period. Hazards ratios and 95% confidence
intervals were calculated for each independent variable in
the multivariable models. Second, we evaluated the asso-
ciation between medication adherence and mortality for
each individual class of medications. Third, we assessed
whether there would be a gradient of benefit between
medication adherence, medication non-adherence, and
not receiving any cardioprotective medications by creat-
ing a three-level categorical variable and entered this vari-
able into our multivariable models. The same
multivariable modeling approach was used as the primary
risk models.
To further assess the robustness of our findings, we per-
formed several additional analyses. Since the ACC/AHA
guidelines do not specifically mention angiotensin recep-
tor blocker medications as an alternative to ACE-inhibi-
tors, we excluded angiotensin receptor blocker
medications from the analysis (3). Second, in separate
regression models, we adjusted for the specific cardiopro-
tective medication prescribed and also the total number
of cardioprotective medications in the medication adher-
ence risk models. Two-way interaction terms between the
number of prescribed cardioprotective medications and
medication adherence were also evaluated in the multi-
variable models. These interaction terms were not statisti-
cally significant and therefore are not presented further.
Third, we re-defined the PDC by changing the minimal
observation time interval window to 240 days. Fourth, we
changed the dichotomization of medication adherence to
a summary PDC ≥ 0.50, ≥ 0.60, ≥ 0.70, and ≥ 0.90. The
analyses were repeated and multivariable regression mod-
els were constructed in a similar fashion as the primary
risk models. The results of these additional analyses were
consistent with our primary findings.
Finally, there were 14 patients who were prescribed at
least 1 cardioprotective medication for less than 90 days
during 2003. A 90-day minimum observation time inter-
val window was chosen initially to ensure stable estimates
for refill adherence. Therefore, in our primary analysis,
these patients were categorized as receiving a cardiopro-
tective medication, but they were excluded from the anal-
ysis on medication adherence. We also performed a series
of sensitivity analyses to confirm our primary findings.
For the cardioprotective medication analysis, we catego-
rized these patients as not receiving a cardioprotective
medication and also excluded these patients in separate
analyses. For the medication adherence risk models, we
categorized these patients as both adherent and non-
adherent in separate analyses. The results of the sensitivity
analysis were consistent with our primary findings.
The study was approved by the Kaiser Permanente Colo-
rado Institutional Review Board. All analyses were per-
formed using the SAS statistical package version 9.1 (SAS
Institute, Cary, NC).
Results
Cardioprotective medications
Baseline characteristics of patients receiving any cardio-
protective medication(s) versus none are listed in Table 1.
The majority of patients (92.8%) received at least 1 or
more cardioprotective medication(s). Among patients
receiving any cardioprotective medications, 78.6%
received 2 or more and 38.7% received all 3 guideline-
indicated medications. Patients receiving cardioprotective
medications were older and had more co-morbidities.
In unadjusted analysis, patients receiving any cardiopro-
tective medication(s) had lower all-cause mortality (7.9%
vs. 11.5%; p = 0.03) compared to patients receiving none
of the medications. In multivariable logistic regression
analysis, patients receiving 1 or more cardioprotective
medication(s) had lower all-cause mortality (OR 0.65;
95% CI 0.43–0.99). Similarly, in Cox proportional haz-
ards models, patients receiving any cardioprotective med-
ication(s) remained at significantly lower risk for death
during the follow-up period (HR 0.67; 95% CI 0.46–
0.97).
Medication adherence
Among patients receiving cardioprotective medications,
baseline characteristics of adherent versus non-adherent
patients are listed in Table 2. The majority of the patients
(80.3%) were adherent, defined as a PDC ≥ 0.80. Adher-
ent patients were older, but had fewer co-morbidities.
They were more likely to be at LDL goal at baseline com-
pared to non-adherent patients.
During follow-up, adherent patients had lower unad-
justed all-cause mortality rates (6.7% vs. 12.1%; p < 0.01).
In multivariable logistic regression analysis, adherent
patients remained at lower risk for all-cause mortality (OR
0.52; 95% CI 0.39–0.69) (Table 3). In Cox proportional
hazards models, adherent patients also had a lower risk
for death due to any cause during the follow-up period
(HR 0.53; 95% CI 0.41–0.68).BMC Cardiovascular Disorders 2006, 6:48 http://www.biomedcentral.com/1471-2261/6/48
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In secondary analysis of the individual classes of medica-
tions, adherence to statin (OR 0.59; 95% CI 0.42–0.87)
and ACE-inhibitor (OR 0.55; 95% CI 0.38–0.78) medica-
tions were also associated with lower risk for all-cause
mortality (Table 3). There was a trend for an association
between adherence to β-blockers and lower mortality,
however it was not statistically significant (OR 0.86; 95%
CI 0.61–1.22). In addition, the association between med-
ication adherence and mortality for the summary measure
and the individual classes of medications was consistent
using different PDC cut-off values to define adherence
(Table 4).
Finally, compared to patients who did not receive any car-
dioprotective medications, patients who were adherent to
medications had lower mortality risk (OR 0.53; 95% CI
0.34–0.81) (Figure 1). However, there was no difference
in mortality between patients receiving cardioprotective
medication who were non-adherent compared to patients
who were not receiving any cardioprotective medications
(OR 1.01; 95% CI 0.64–1.61).
Discussion
The objective of this study was to evaluate the association
between cardioprotective medication adherence and mor-
tality among patients with diabetes and IHD. We found
that patients receiving 1 or more cardioprotective medica-
tion(s) had lower all-cause mortality compared to
patients receiving none of the medications. In addition,
among those receiving cardioprotective medication(s),
adherent patients were at lower risk for all-cause mortality
compared to non-adherent patients. In contrast, patients
receiving cardioprotective medications who were non-
adherent had similar mortality risk to patients receiving
none of the cardioprotective medications. These findings
suggest that current quality improvement efforts should
be expanded to include the assessment of medication
adherence as a key component of secondary prevention
care in addition to the prescription of indicated medica-
tions.
Clinical trials have demonstrated the efficacy of medica-
tions such as β-blockers, ACE inhibitors, and statin medi-
cations [3,17,18]. However, the effectiveness of
combinations of these medications remains less well
defined among patients with chronic IHD. Prior studies
have demonstrated a mortality benefit among high-risk
IHD patients prescribed combinations of cardioprotective
medications after acute coronary syndrome presentation
[19,20]. However, among patients with IHD and diabetes,
only 11% of patients were prescribed the combination of
antiplatelet agent, ACE-inhibitor, and statin medications
[21]. In our study, 78.6% of patients were receiving 2 or
more medications and 38.7% were receiving all 3 cardio-
protective medications. In addition, patients receiving any
cardioprotective medication had lower mortality com-
pared to those receiving none of the medications. Our
findings demonstrate the effectiveness for combinations
of cardioprotective medications and are consistent with
national guideline recommendations that patients with
diabetes and IHD should receive all of these therapies
unless contraindications exist.
Studies evaluating medication adherence using pharmacy
refill records among IHD patients suggest that non-adher-
ence is a common phenomenon, but have typically
Table 2: Baseline characteristics of patients according to medication adherence (n = 3,696).
Variable Non-adherent (n = 728) Adherent (n = 2968) p-value
Male 58.9 62.0 0.13
Age, mean (STD) 67.7(11.3) 69.6(9.5) <0.01
Hypertension 91.8 92.3 0.59
Prior myocardial infarction 49.3 45.7 0.08
Peripheral vascular disease 11.8 9.5 0.07
Cerebrovascular disease 35.8 33.1 0.16
Chronic obstructive pulmonary disease 31.6 27.7 0.04
Heart failure 41.6 34.4 <0.01
Sleep apnea 25.0 22.8 0.21
Renal insufficiency 19.0 14.1 <0.01
Retinopathy 8.2 6.1 0.03
Hypercholesterolemia 81.5 85.5 <0.01
Statin prescription 66.7 75.1 <0.01
ACEI or ARB prescription 71.0 76.0 <0.01
β-blocker prescription 62.2 66.3 0.04
Blood pressure <130/80 mm Hg at baseline 39.3 39.5 0.91
LDL cholesterol <100 mg/dl at baseline 68.8 74.8 <0.01
Hemoglobin A1C <7% at baseline 46.1 45.9 0.88
ACEI: Angiotensin-converting enzyme inhibitor ARB: Angiotensin Receptor BlockerBMC Cardiovascular Disorders 2006, 6:48 http://www.biomedcentral.com/1471-2261/6/48
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focused on a single medication, and/or have not assessed
the impact of non-adherence on outcomes. Wei, et al. pre-
viously demonstrated that patients adherent to β-blockers
or statins had better outcomes compared to patients who
were not prescribed either of these medications [14,15].
Blackburn, et al. found that patients adherent to statin
medications were also more likely to adhere to β-blockers
and ACE inhibitors. However, at 2-years from the index
statin prescription, only 36.1% of patients with chronic
IHD were still adherent with statins [22]. In our study, the
proportion of adherent patients (80.3%) was higher than
in other populations; and adherent patients had lower all-
cause mortality compared to either non-adherent patients
or patients not receiving any cardioprotective medica-
tions. These findings suggest that medication adherence
should be routinely assessed and once identified, clini-
cians should approach medication non-adherence like an
elevated systolic blood pressure reading or high LDL cho-
lesterol, a risk marker for adverse outcomes that requires
treatment and follow-up.
The association between medication adherence and mor-
tality is likely mediated through direct and indirect mech-
anisms. In clinical trials, both statin and ACE-inhibitor
medications have been shown to benefit patients with
IHD, diabetes or both of these conditions [3]). The mag-
nitude of mortality benefit seen in our study, however,
was greater than the benefit demonstrated in clinical trials
of these medications suggesting that medication adher-
ence may also be correlated with self-care behaviors that
are directly or indirectly related to outcomes [23-26]. For
example, medication adherence has been associated with
better outcomes regardless of treatment assignment in
randomized controlled clinical trials [16,26-28]. Adher-
ent patients may be more likely to follow lifestyle recom-
mendations and other healthy behaviors leading to
improved outcomes. Regardless of the mechanism, inter-
ventions are needed to improve adherence to medications
as well as healthy lifestyle behaviors among patients with
diabetes and IHD.
There was a trend for benefit of β-blockers adherence and
improved outcomes among patients with diabetes and
IHD, however it was not statistically significant. β-block-
ers have been shown to improve survival among patients
presenting with an acute myocardial infarction and after
recent ST elevation myocardial infarction (STEMI) [29]. In
contrast, the benefit of β-blockers in patients with stable
angina without prior MI or among those with a remote MI
is less well defined. In a meta-analysis of randomized tri-
als of patients with stable angina, there was no benefit of
β-blockers compared to calcium channel blockers in
reducing the composite endpoint of death or MI (OR
1.06; 95% CI 0.73–1.54) [3]. In our study, less than 50%
of patients with IHD had a prior MI. In addition, because
of our administrative data source, we cannot be certain
about the timing of the prior MI event. These factors may
have biased our results toward the null and the lack of a
statistically significant association between β-blockers
adherence and mortality. Nevertheless, β-blockers are
effective antianginal medications and recommended by
national guidelines for patients with chronic stable angina
[3].
Several potential limitations of this study should be
addressed. First, this was a single MCO study using
Table 3: The association between medication adherence and mortality.
Adherence measure N Percent adherent (PDC ≥ 0.80) All-cause mortality
Unadjusted OR (95% CI) Adjusted OR (95% CI)
Summary measure 3696 80.3% 0.52 (0.40–0.68) 0.52 (0.39–0.69)
β-blocker medications 2440 76.6% 0.72 (0.52–1.00) 0.86 (0.61–1.22)
Statin medications 2833 81.9% 0.65 (0.45–0.94) 0.59 (0.41–0.87)
ACE-inhibitor medications 2379 80.0% 0.56 (0.40–0.80) 0.55 (0.38–0.78)
Table 4: The association between medication adherence and mortality for different cut-offs of the PDC.
PDC cut-off for 
adherence
Summary measure OR 
(95% CI)
B-blocker OR (95% CI) Statin OR (95% CI) ACE-inhibitor OR (95% CI)
≥0.50 0.49 (0.30–0.80) 0.93 (0.55–1.56) 0.63 (0.34–1.15) 0.48 (0.28–0.81)
≥0.60 0.46 (0.31–0.67) 0.83 (0.55–1.26) 0.60 (0.37–0.98) 0.48 (0.31–0.73)
≥0.70 0.45 (0.33–0.61) 0.88 (0.61–1.28) 0.58 (0.38–0.88) 0.47 (0.32–0.69)
≥0.80 0.52 (0.39–0.69) 0.86 (0.61–1.22) 0.59 (0.41–0.87) 0.55 (0.38–0.78)
≥0.90 0.66 (0.51–0.86) 0.83 (0.60–1.14) 0.66 (0.47–0.93) 0.61 (0.43–0.85)BMC Cardiovascular Disorders 2006, 6:48 http://www.biomedcentral.com/1471-2261/6/48
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administrative data and we did not have data on cause of
death. However, it was a population-based study of a large
integrated healthcare delivery organization. Second, our
inclusion criteria may not have identified all patients with
IHD in the diabetes registry, however, the criteria used are
highly specific and have a high positive predictive value
for identifying patients with IHD [8]. Third, adherence
was based on pharmacy refill records. However, 98% of
the patients had prescription drug coverage and the small
proportion of missing data would, if anything, tend to
bias the results toward the null. Pharmacy refill records
have been found to be highly correlated with electronic
adherence monitoring and the act of refilling a medica-
tion is the first step towards taking a medication, reflecting
the patients' active decision to continue with therapy
[30]). Fourth, the categorization of adherent patients
based on a PDC ≥ 0.80 versus <0.80 was somewhat arbi-
trary. This dichotomization of adherence, however, was
consistent with the literature [10-16]. Furthermore, we
examined the effect of medication adherence on out-
comes using multiple different cut-points for dichotomiz-
ing adherence (i.e., PDC ≥ 0.50, ≥ 0.60, ≥ 0.70, or ≥ 0.90).
Regardless of the cut-point, the association between
adherence and improved outcomes was consistent. Fifth,
we did not assess for specific contraindications to medica-
tions. However, our definition for receipt of any cardio-
protective medication(s) was broadly defined and
patients only had to receive any one of four indicated
medications for patients with diabetes and IHD. Future
studies should assess the reasons why patients did not
receive the indicated cardioprotective medication(s) and
also determine if overall pill burden impacts medication
adherence. Finally, we did not assess adherence to aspirin
because it is often obtained over the counter or adherence
to thienopyridines because it is a class IIa recommenda-
tion for secondary prevention among patients with
chronic CAD. Our main focus was on class I indicated
medications, including ACE-inhibitors, β-blockers, and
statin, for patients with CAD and diabetes.
Conclusion
We found that among those receiving cardioprotective
medication(s), adherent patients were at lower risk for all-
cause mortality compared to non-adherent patients. In
contrast, patients receiving cardioprotective medications
who were non-adherent had similar mortality risk to
The association between receipt of cardioprotective medications, medication adherence and mortality Figure 1
The association between receipt of cardioprotective medications, medication adherence and mortality.
1.0
Receipt of any medication(s) vs. none 
(OR 0.65; 95% CI 0.43-0.99) 
Adherent vs. non-adherent 
(OR 0.52; 95% CI 0.39-0.69) 
Adherent vs. no medication 
(OR 0.53; 95% CI 0.34-0.81) 
Non-adherent vs. no medication 
(OR 1.01; 95% CI 0.64-1.61) 
0.5 2.0
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patients receiving none of the cardioprotective medica-
tions. Our findings suggest that medication non-adher-
ence should be routinely assessed and once identified,
clinicians should engage patients in a discussion of the
reasons for non-adherence and promote ways of improv-
ing adherence to prescribed medications. Finally, quality
improvement interventions are needed to increase medi-
cation adherence among patients with diabetes and IHD
to maximize the benefit of cardioprotective medications.
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